PRF Technologies (PRFX)
Develops sustained-release therapies and software for solar-asset monitoring and optimization.
Why Is PRF Tech Stock Falling On Monday?
PRF Technologies (NASDAQ: PRFX) stock falls sharply Monday morning. Read why analysts see this as a market correction after Friday's 186% surge.
Short Interest in PainReform Ltd. (NASDAQ:PRFX) Drops By 13.3%
PainReform Ltd. (NASDAQ: PRFX - Get Free Report) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 68,090 shares, a decrease of 13.3% from the February 26th total of 78,499 shares. Approximately 25.8% of the shares of the company are sold
PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push
Penny stock PainReform Ltd. (NASDAQ: PRFX) stock climbed on Friday following the company's recent announcement of a name change to PRF Technologies Ltd.
PainReform Ltd. Changes Name to PRF Technologies Ltd.
Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus Shareholders Approved Name Change at January 6, 2026 Annual General Meeting as Company Evolves Beyond Single-Asset Focus
PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies
TEL AVIV, Israel, Jan. 12, 2026 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on reformulating established therapeutics for post-operative pain management, together with its majority-owned subsidiary LayerBio, Inc., today announced safety data supporting the continued development of OcuRing™-K drop-less, sustained-release ocular drug delivery platform for use in cataract surgery.
PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison
PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk. Insider and Institutional Ownership 37.3% of PainReform shares
PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market
New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions New lifecycle-wide audit platform provides complete data coverage, advanced diagnostics, and rapid turnaround, supporting investors, operators, insurers and lenders across commissioning, underperformance, warranty expiry, and asset transactions
PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities
TEL AVIV, Israel, Dec. 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that its pharmaceutical division has completed an R&D assessment of LayerBio's proprietary drop-less, sustained-release ocular drug-delivery platform.
PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy
Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market Development plan positions OcuRing™-K for advancement in the fast-growing, multi-billion-dollar global cataract surgery market
PainReform (NASDAQ:PRFX) Trading Down 1.3% – Here’s Why
PainReform Ltd. (NASDAQ: PRFX - Get Free Report) dropped 1.3% during mid-day trading on Monday. The stock traded as low as $0.87 and last traded at $0.8838. Approximately 96,867 shares changed hands during mid-day trading, a decline of 86% from the average daily volume of 695,639 shares. The stock had previously closed at $0.8955. Analyst
PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis
TEL AVIV, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that DeepSolar, its solar energy business unit developing next-generation AI analytics, has advanced the development of its proprietary automated reporting engine, designed to transform how solar-asset performance is analyzed, understood, and communicated.
PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects
TEL AVIV, Israel, Nov. 05, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced that DeepSolar, its solar energy business unit developing next-generation AI-driven solar analytics, was recently featured in a Watchlist Interview produced in collaboration with The Market Link, highlighting its participation in the NVIDIA Connect program.
PainReform Provides Business Update for the Six Months Ended June 30, 2025
TEL AVIV, Israel, Oct. 01, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a specialty pharmaceutical company focused on the reformulation of established therapeutics and commercialization of AI-driven solar analytics technologies, today provided a business update for the six months ended June 30, 2025.
Nvidia enrollment sends this stock soaring 130%
Shares of Israel-based pharmaceutical company PainReform (NASDAQ: PRFX) jumped nearly 130% on Tuesday after its renewable energy arm, DeepSolar, was accepted into the Nvidia (NASDAQ: NVDA) Connect Program.
PainReform/DeepSolar Accepted into NVIDIA Connect Program
Acceptance to NVIDIA Connect Program offers access to unique tools for the development of DeepSolar's nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy by up to 50% and optimize energy asset performance Acceptance to NVIDIA Connect Program offers access to unique tools for the development of DeepSolar's nextgen, AI-driven, solar forecasting platform to improve weather prediction accuracy by up to 50% and optimize energy asset performance
PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System
Acquisition of Majority Equity Interest in LayerBio and its OcuRing™-K Technology Targets Growing Demand for ‘Dropless' Solutions in Ophthalmic Surgery Acquisition of Majority Equity Interest in LayerBio and its OcuRing™-K Technology Targets Growing Demand for ‘Dropless' Solutions in Ophthalmic Surgery
PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio
TEL AVIV, Israel, July 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced, through its pharmaceutical division, the signing of a strategic investment agreement with LayerBio Inc., a privately held Boston biotechnology company developing proprietary, long-acting, non-opiate treatments for ophthalmic surgery.
Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales
As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel , May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on the Tel Aviv Stock Exchange, announced the achievement of a first milestone in the transaction involving the sale of its DeepSolar operations to PainReform (NASDAQ: PRFX).
PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects
TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The project will utilize PainReform's proprietary DeepSolar™ platform, an AI-powered optimization solution designed to enhance operational efficiency and energy yield at utility-scale solar facilities. The pilot will be conducted at Econergy's 92-megawatt (MW) photovoltaic plant in Parau, Romania—one of the country's largest operational solar projects.
PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market
TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven software solutions designed to optimize solar energy usage in residential and utility-scale solar power plants.